UniProtKB/SwissProt variant VAR

Variant information

Variant position:

363

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LB/B

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Arginine (R) to Histidine (H) at position 363 (R363H, p.Arg363His).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from large size and basic (R) to medium size and polar (H)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

0

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Other resources:

Links to websites of interest for the variant.

Variant rs11556924 [ dbSNP | Ensembl ]

Sequence information

Variant position:

363

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

502

The length of the canonical sequence.

Location on the sequence:

KSPGPIVSRTRSWDSSSPVD R PEPEAASPTTRTRPVTRSMG

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KSPGPIVSRTRSWDSSSPVDRPEPEAASPTTRTRPVTRSMG

Mouse                         KSPGPIVSRTRSWESSSPVDRPELEAASPTTRSRPVTRSMG

Xenopus laevis                QSPAFAYGRTRSSDLLSPAD-------SEAVRNRPVTRSMG

Xenopus tropicalis            QSPALAYGRTRSSDLLSPAD-------SEAVRSRPVTRSMG

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 502	Nuclear-interacting partner of ALK
Modified residue	344 – 344	Phosphoserine
Modified residue	354 – 354	Phosphoserine
Modified residue	359 – 359	Phosphoserine
Modified residue	370 – 370	Phosphoserine
Modified residue	381 – 381	Phosphoserine
Alternative sequence	341 – 411	Missing. In isoform 3.
Mutagenesis	354 – 354	S -> A. Strongly reduces phosphorylation and induces the formation of a constitutive SCF(NIPA) E3 complex that degrades CCNB1 at G2/M phase and delays mitotic entry.

Literature citations

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1); VARIANTS ALA-271 AND HIS-363;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q86WB0: Variant p.Arg363His